Hong Kong stocks in the innovative pharmaceutical sector continue to decline, with Gilead Sciences falling more than 14%.

Hong Kong stocks in the innovative pharmaceutical concept continued to decline, with Gilead Sciences falling more than 14%, China Biologic Products falling more than 9%, BeiGene and Sino Biopharmaceutical also following the decline.